1. Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways.
- Author
-
Hsieh HY, Shen CH, Lin RI, Feng YM, Huang SY, Wang YH, Wu SF, Hsu CD, and Chan MW
- Subjects
- Angiopoietin-Like Protein 4, Angiopoietins genetics, Animals, Apoptosis drug effects, Cell Line, Tumor, G1 Phase Cell Cycle Checkpoints drug effects, Glycogen Synthase Kinase 3 beta, Humans, Mice, Mice, Inbred BALB C, Receptors, Serotonin analysis, Signal Transduction physiology, TOR Serine-Threonine Kinases physiology, Tuberous Sclerosis Complex 2 Protein, Tumor Suppressor Proteins physiology, Urinary Bladder Neoplasms pathology, beta Catenin physiology, Antineoplastic Agents pharmacology, Cyproheptadine pharmacology, Glycogen Synthase Kinase 3 antagonists & inhibitors, Signal Transduction drug effects, TOR Serine-Threonine Kinases antagonists & inhibitors, Urinary Bladder Neoplasms drug therapy, beta Catenin antagonists & inhibitors
- Abstract
Cyproheptadine, a serotonin antagonist, has recently been reported to function as a novel therapeutic agent by inhibiting PI3K/AKT signaling in several human cancers. However, the therapeutic effect of cyproheptadine in urothelial carcinoma (UC) has never been explored. In this study, we determined the effect of cyproheptadine on the growth of five human UC cell lines and an in vivo xenograft model. The results showed that cyproheptadine exerted an inhibitory effect on the proliferation of UC cells both in vitro and in vivo. Cyproheptadine also induced cell cycle arrest in the G1 phase, subsequently followed by apoptosis and necrosis. The underlying mechanisms of cell cycle arrest were associated with the reduction of c-Myc, induction of p21 and p27, and the stabilization of Rb expression. In addition, the suppression of the GSK3β/TSC2/mTOR pathway and deregulation of the GSK3β/β-catenin signaling were observed in cyproheptadine-treated UC cells. Furthermore, cyproheptadine-induced apoptosis was associated with ANGPTL4 expression followed by activation of caspase3 and PARP in UC cells. Our experimental results provide evidence that cyproheptadine is a suitable therapeutic agent for the treatment of UC., (Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF